Immuron LimitedASX: IMC

Immuron Announces Travelan Clinical Trial Update

· Issued by Immuron Limited

Filed with ASX · · 4 pages · English

Summary by 6ix AI

The trial demonstrated statistically significant reductions in antibody levels and improved microbiome stability in participants receiving Travelan compared to those on placebo. This update reflects Immuron's ongoing commitment to developing Travelan as a treatment for travelers' diarrhea caused by pathogenic bacteria.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Immuron Limited on 6ix

Earlier from Immuron

Later from Immuron

All Immuron news releases